Litfulo - direct healthcare professional communication (DHPC)

ritlecitinib tosilate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Litfulo (ritlecitinib): Updated recommendations to minimise the risks of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality

Key facts

• Medicine name:
  Litfulo
• Active substance:
  ritlecitinib tosilate
• Therapeutic area (MeSH):
  Alopecia Areata
• Regulatory outcome:
  Variation
• DHPC type:
  • Adverse event
  • Post-authorisation measure
  • Restriction of indication
• Human ATC codes:
  L04AF08
• Dissemination date:
  10/08/2026